Cartesian Therapeutics, Inc. (RNAC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.27+1.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RNAC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 109.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -74.9% |
Growth built into the price is above our model estimate.
The price assumes 184.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
RNAC — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…
Dated 2026-05-26
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Why it matters: Having cash on hand is important for trials and operations until 2028.
Watch forCash resources stay the same or increase. This helps operations run smoothly.
Also watch forCash resources drop a lot, raising worries about funding trials.
Why it matters: This data is crucial for the future of Descartes-08 in treating myasthenia gravis. A positive outcome could lead to a BLA filing and potential market entry.
Supportive ifTopline data shows a big improvement in MG Activities of Daily Living (MG-ADL) score. The score improved by three points or more.
Worry ifTopline data shows no big change in MG-ADL score when compared to placebo.
Why it matters: Having enough cash is key for ongoing trials and operations. Good news could boost investor confidence.
Supportive ifManagement says cash will last into 2028 and more financing is secured.
Worry ifManagement warns there may be cash shortages or delays in getting financing.
Why it matters: This partnership aims to enhance the delivery of CAR-T therapies. Success could lead to new treatment options.
Supportive ifUpdates show the Phase 1 trial with WestGene started well and has good early data.
Worry ifUpdates show delays or problems in the partnership or starting the trial.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$262 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $849 loss on $10,000 · 8.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,511 loss on $10,000 · 45.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Completing this trial is crucial for the product's future. Delays could hurt the company’s prospects.
Worry ifThe trial is completed on schedule with all patient data collected by mid-2027.
Less concerning ifThe trial is delayed beyond mid-2027 without a valid reason.
Why it matters: Data will inform the next steps for Descartes-08 in treating myositis. This could lead to pivotal trials.
Supportive ifData from the Phase 2 TRITON trial shows good safety and effectiveness results.
Worry ifData from the Phase 2 TRITON trial shows no good results for safety or effectiveness.
Why it matters: Data will show how Descartes-08 helps kids with juvenile dermatomyositis. This is key for using the treatment more.
Supportive ifData from the Phase 1/2 HELIOS trial shows positive outcomes in pediatric patients.
Worry ifData from the Phase 1/2 HELIOS trial shows no positive outcomes in pediatric patients.
Why it matters: Topline data will show how well Descartes-08 works for myasthenia gravis. This is a key step toward FDA approval.
Supportive ifTopline data from the Phase 3 AURORA trial is reported in Q1 2027 with positive results.
Worry ifThe main data shows no big change in MG-ADL scores compared to placebo.
Why it matters: Data will guide the next steps for Descartes-08 in treating myositis.
Supportive ifData from some patients shows Descartes-08 is safe and works better than placebo.
Worry ifData shows no clear path to a pivotal trial for myositis treatment.
Why it matters: Updates can signal management's confidence in the company's value. It may also support the stock price.
Supportive ifManagement says they finished a big part of the buyback program.
Worry ifManagement cancels or cuts back on the buyback program.